Treatment options in severe allergic asthma | Paraschiva Chereches-Panta |
Summary :
Severe allergic asthma in children has a relatively low prevalence among total number of asthma patients. The main goal of the long-term treatment is achieving disease control as defined by the guidelines. Current therapeutic options in allergic asthma include several alternatives that offer the possibility to personalize the treatment in these severe forms. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E. It is the first biological agent that was approved in children with severe allergic asthma. We present a series of patients treated with Omalizumab in the IIIrd Pediatric University Hospital In Cluj-Napoca, Romania over a period of 9 years. The main outcomes that we analyzed are the number an severeity of exacerbations, the presence of symptoms between exacerbations, pulmonary function tests and asthma control test (ACT).
About Author :
Doctoral Degree in Medicine (2001): “Monitoring of treatment with theophylline administered in children with asthma and in prematures with idiopathic apnea by measuring salivary level of the drug”. Lecturer in Pediatrics (2002) at The University of Medicine and Pharmacy “Iuliu Hațieganu”, Dpt. 9, Disc. Pediatric III, Cluj Napoca Overspecialisation in Paediatric Pneumology Competence in “ Special Pulmonary Function Tests” Competence in Pediatric Allergology and Immunology Member of The Pediatric Pneumology Committee of the Ministry of Health (since 2019).
